Free Float 70,41 %
Shares Float 616.150,00
Shares Outstanding 875.150,00
Epigenomics AG
Share · DE000A11QW50 (XETR)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Epigenomics AG
No Price
Share Float & Liquidity
Company Profile for Epigenomics AG Share
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Company Data
Name Epigenomics AG
Company Epigenomics AG
Website
https://www.epigenomics.com
Primary Exchange 
XETRA
XETRA
ISIN DE000A11QW50
Asset Class Share
Sector Healthcare
Industry Medical - Diagnostics & Research
CEO Noel Thomas Doheny
Country Germany
Currency EUR
Employees 0,0 T
Address Geneststrasse 5, 10829 Berlin
IPO Date 2004-07-19
Stock Splits
| Date | Split |
|---|---|
| 08.12.2023 | 1:5 |
| 27.12.2022 | 4:1 |
| 03.05.2021 | 1019:1000 |
| 11.12.2020 | 1:8 |
Ticker Symbols
| Name | Symbol |
|---|---|
| XETRA | ECX.DE |
More Shares
Investors who hold Epigenomics AG also have the following shares in their portfolio:
